Puma Biotechnology Inc. said its investigational breast-cancer treatment showed a 33% improvement in disease-free survival over a placebo in a phase III study.
WSJ.com: US Business, Wall Street Journal: Business
Tue, 07/22/2014 - 2:17pm
Puma Biotechnology Inc. said its investigational breast-cancer treatment showed a 33% improvement in disease-free survival over a placebo in a phase III study.